C. Mauguen , A. Maruani , S. Barbarot , C. Abasq , L. Martin , J. Herbert , T. Goronflot , P.-A. Gourraud , A. Happe , A. Descatha , J.-M. Chrétien , A. Beuchée , H. Adamski , A. Dupuy , G. Bouzillé , E. Oger , C. Droitcourt
{"title":"口服普萘洛尔治疗至少六个月的儿童婴儿血管瘤早期复发的相关因素:一项使用2014-2021法国Ouest数据中心的病例对照研究。","authors":"C. Mauguen , A. Maruani , S. Barbarot , C. Abasq , L. Martin , J. Herbert , T. Goronflot , P.-A. Gourraud , A. Happe , A. Descatha , J.-M. Chrétien , A. Beuchée , H. Adamski , A. Dupuy , G. Bouzillé , E. Oger , C. Droitcourt","doi":"10.1016/j.annder.2023.03.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p><span><span>The factors associated with early relapse of infantile haemangioma (IH) after a first course of </span>treatment with oral </span>propranolol for at least six months (initiated after the marketing authorization had been granted) have not previously been investigated.</p></div><div><h3>Objectives</h3><p>To identify factors associated with the risk of early relapse in children with IH treated with oral propranolol according to the current prescribing guidelines.</p></div><div><h3>Methods</h3><p>We performed a multicentre, retrospective, case-control study, using the Ouest Data Hub database. All children treated for at least 6 months with oral propranolol for IH between 31 June 2014 and 31 December 2021, and with a follow-up visit at least three months after treatment discontinuation were included. A case was defined as relapse of IH within three months of treatment discontinuation; each case was matched for age at treatment initiation and for centre, with four (relapse-free) controls. The association between relapse and treatment or IH characteristics was expressed as an odds ratio (OR) from univariate and multivariate conditional logistic regressions.</p></div><div><h3>Results</h3><p>A total of 225 children were included. Of these, 36 (16%) relapsed early. In a multivariate analysis, a deep IH component was a risk factor for early relapse [OR = 8.93; 95%CI: 1.0–78.9, p = 0.05]. A propranolol dosage level of less than 3 mg/kg/day protected against early relapse [OR = 0.11; 95%CI: 0.02–0.7, p = 0.02]. Tapering before propranolol discontinuation was not associated with a lower risk of early relapse.</p></div><div><h3>Conclusion</h3><p>The risk factors for late and early relapse are probably different. Investigation of the risk factors for early vs. late IH relapse is now warranted.</p></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Factors associated with early relapse of infantile haemangioma in children treated for at least six months with oral propranolol: A case-control study using the 2014–2021 French Ouest DataHub\",\"authors\":\"C. Mauguen , A. Maruani , S. Barbarot , C. Abasq , L. Martin , J. Herbert , T. Goronflot , P.-A. Gourraud , A. Happe , A. Descatha , J.-M. Chrétien , A. Beuchée , H. Adamski , A. Dupuy , G. Bouzillé , E. Oger , C. Droitcourt\",\"doi\":\"10.1016/j.annder.2023.03.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p><span><span>The factors associated with early relapse of infantile haemangioma (IH) after a first course of </span>treatment with oral </span>propranolol for at least six months (initiated after the marketing authorization had been granted) have not previously been investigated.</p></div><div><h3>Objectives</h3><p>To identify factors associated with the risk of early relapse in children with IH treated with oral propranolol according to the current prescribing guidelines.</p></div><div><h3>Methods</h3><p>We performed a multicentre, retrospective, case-control study, using the Ouest Data Hub database. All children treated for at least 6 months with oral propranolol for IH between 31 June 2014 and 31 December 2021, and with a follow-up visit at least three months after treatment discontinuation were included. A case was defined as relapse of IH within three months of treatment discontinuation; each case was matched for age at treatment initiation and for centre, with four (relapse-free) controls. The association between relapse and treatment or IH characteristics was expressed as an odds ratio (OR) from univariate and multivariate conditional logistic regressions.</p></div><div><h3>Results</h3><p>A total of 225 children were included. Of these, 36 (16%) relapsed early. In a multivariate analysis, a deep IH component was a risk factor for early relapse [OR = 8.93; 95%CI: 1.0–78.9, p = 0.05]. A propranolol dosage level of less than 3 mg/kg/day protected against early relapse [OR = 0.11; 95%CI: 0.02–0.7, p = 0.02]. Tapering before propranolol discontinuation was not associated with a lower risk of early relapse.</p></div><div><h3>Conclusion</h3><p>The risk factors for late and early relapse are probably different. Investigation of the risk factors for early vs. late IH relapse is now warranted.</p></div>\",\"PeriodicalId\":7900,\"journal\":{\"name\":\"Annales De Dermatologie Et De Venereologie\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annales De Dermatologie Et De Venereologie\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0151963823000376\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales De Dermatologie Et De Venereologie","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0151963823000376","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Factors associated with early relapse of infantile haemangioma in children treated for at least six months with oral propranolol: A case-control study using the 2014–2021 French Ouest DataHub
Background
The factors associated with early relapse of infantile haemangioma (IH) after a first course of treatment with oral propranolol for at least six months (initiated after the marketing authorization had been granted) have not previously been investigated.
Objectives
To identify factors associated with the risk of early relapse in children with IH treated with oral propranolol according to the current prescribing guidelines.
Methods
We performed a multicentre, retrospective, case-control study, using the Ouest Data Hub database. All children treated for at least 6 months with oral propranolol for IH between 31 June 2014 and 31 December 2021, and with a follow-up visit at least three months after treatment discontinuation were included. A case was defined as relapse of IH within three months of treatment discontinuation; each case was matched for age at treatment initiation and for centre, with four (relapse-free) controls. The association between relapse and treatment or IH characteristics was expressed as an odds ratio (OR) from univariate and multivariate conditional logistic regressions.
Results
A total of 225 children were included. Of these, 36 (16%) relapsed early. In a multivariate analysis, a deep IH component was a risk factor for early relapse [OR = 8.93; 95%CI: 1.0–78.9, p = 0.05]. A propranolol dosage level of less than 3 mg/kg/day protected against early relapse [OR = 0.11; 95%CI: 0.02–0.7, p = 0.02]. Tapering before propranolol discontinuation was not associated with a lower risk of early relapse.
Conclusion
The risk factors for late and early relapse are probably different. Investigation of the risk factors for early vs. late IH relapse is now warranted.
期刊介绍:
Les Annales de dermatologie sont le rendez-vous mensuel incontournable de toute la dermatologie francophone, grâce à leur comité de rédaction qui assure une sélection rigoureuse des articles selon les normes de l''édition scientifique internationale.
Une revue didactique, véritable aide à la pratique médicale quotidienne
Pour compléter et enrichir la partie scientifique, la rubrique Formation médicale continue propose aux lecteurs des textes didactiques et interactifs (Cas pour diagnostic, Notes de pharmacovigilance, la Question du praticien, Dermatologie chirurgicale, la Sélection bibliographique du mois...) qui les font bénéficier d''une formation post-universitaire diversifiée et de qualité. La revue consacre également un espace pour la publication de questions des lecteurs auxquelles des experts apportent une réponse.